Skip to main
GMAB

GMAB Stock Forecast & Price Target

GMAB Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Genmab's recent financial performance indicates a strong outlook, highlighted by an operating income that exceeded expectations by 20% while revenues met the market's predictions. With an impressive lineup of near-term clinical catalysts expected over the next 12-18 months, notably in their expanding pipeline, Genmab is poised to enhance product revenue forecasts and strengthen its market position. Furthermore, the company's robust balance sheet, ending Q3 2025 with approximately $3.4 billion in cash and equivalents, positions it favorably to navigate challenges in the biotech sector and supports ongoing growth initiatives.

Bears say

Genmab faces multiple risks that contribute to a negative outlook, particularly the slowing sales of its leading product, Darzalex, which may impact revenue stability. Furthermore, the company is experiencing challenges with key pipeline candidates, including the discontinuation of GEN1042 and the potential competitive threats from emerging therapies, which could hinder future growth opportunities. Additionally, there are overarching concerns such as clinical or regulatory failures of pipeline products and macroeconomic factors that may further exacerbate financial performance uncertainties.

GMAB has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Genmab - ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Genmab - ADR (GMAB) Forecast

Analysts have given GMAB a Strong Buy based on their latest research and market trends.

According to 4 analysts, GMAB has a Strong Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $39.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $39.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Genmab - ADR (GMAB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.